Clinical trials: Hypertensive Patients
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the…
- Trial name
- NCT00386607
- Testing
- Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 601 people
- Sponsor
- Novartis
Hypertension
Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
Hypertension (HTN) is the single most prevalent risk factor for cardiovascular disease, diabetes, obesity and metabolic syndrome.
- Trial name
- NCT02133872
- Testing
- Minocycline 50mg/d, Minocycline 100mg/d, Minocycline 200mg/d
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Florida
Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure.
- Trial name
- NCT00425373
- Testing
- Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg
- Where
- Japan
- Volunteers
- 1,474 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
- Trial name
- NCT00770861
- Testing
- Nebivolol
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 277 people
- Sponsor
- Forest Laboratories
Hypertension, Chronic Kidney Disease
Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients
The purpose of this study is to determine whether aliskiren is effective in the treatment of blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease (CKD) patients.
- Trial name
- NCT01284114
- Testing
- Aliskiren
- Where
- 4 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Jichi Medical University
Hypertension
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
- Trial name
- NCT01876368
- Testing
- LCZ696, Olmesartan
- Where
- 51 sites in United States, Argentina and 5 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Implementing Evidence Based Treatment of Hypertension
This study examines the use of patient initiated discussions of blood pressure medication in the primary care setting. Additionally, this study examines different levels of patient incentive(s) to initiate discussions with…
- Trial name
- NCT00265538
- Testing
- Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C)
- Where
- 2 sites in United States
- Volunteers
- 834 people
- Sponsor
- VA Office of Research and Development
Essential Hypertension
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430508
- Testing
- olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil/hydrochlorothiazide tablets
- Where
- 55 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 972 people
- Sponsor
- Daiichi Sankyo
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Hypertension
Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)
This study was designed to evaluate the pharmacodynamics of a bolus dosing regimen of clevidipine, a vascular-selective L-type calcium channel antagonist, for the management of blood pressure in cardiac surgery patients, as well…
- Trial name
- SPRINT (NCT00799604)
- Testing
- clevidipine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- The Medicines Company
Mild to Moderate Hypertension
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
- Trial name
- NCT06423352
- Testing
- Zilebesiran
- Where
- 3 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension, Metabolic Disorder
A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
- Trial name
- NCT00546052
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 1,738 people
- Sponsor
- Organon and Co
Hypertension
A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes
The aim of this 12-week, multicenter, interventional, prospective, open-label and single-arm study is to evaluate the safety and efficacy of 5 milligram per day (mg/day) and 10 mg/day bisoprolol in Filipino hypertensive subjects…
- Trial name
- NCT01190436
- Testing
- Bisoprolol
- Where
- Philippines
- Volunteers
- 125 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hypertension
A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy
This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.
- Trial name
- NCT00785512
- Testing
- Nebivolol
- Where
- 26 sites in United States
- Volunteers
- 207 people
- Sponsor
- Forest Laboratories
Hypertension
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients
The in-MAU-tion study is conducted to determine the percentage of hypertensive participants with or without diabetes reaching CHEP (Canadian Hypertension Education Program) defined blood pressure targets.
- Trial name
- in-MAU-tion (NCT01078584)
- Where
- 568 sites in Canada
- Volunteers
- 7,993 people
- Sponsor
- Abbott
Diabetes, Hypertension
Adherence and Intensification of Medications (AIM) Implementation Study
Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving.
- Trial name
- NCT00495794
- Testing
- Clinical pharmacist-based intervention
- Where
- United States
- Volunteers
- 4,622 people
- Sponsor
- US Department of Veterans Affairs
Hypertension
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
- Trial name
- NCT00396656
- Testing
- Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis
Hypertension
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg.
- Trial name
- NCT00909038
- Where
- 915 sites in France
- Volunteers
- 2,411 people
- Sponsor
- Boehringer Ingelheim
Hypertension
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and < 110 mmHg).
- Trial name
- NCT00402103
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 556 people
- Sponsor
- Novartis